| 1.31 0.04 (3.15%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.95 |
1-year : | 2.4 |
| Resists | First : | 1.67 |
Second : | 2.05 |
| Pivot price | 1.49 |
|||
| Supports | First : | 1.04 | Second : | 0.87 |
| MAs | MA(5) : | 1.27 |
MA(20) : | 1.52 |
| MA(100) : | 1.07 |
MA(250) : | 1.04 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.7 |
D(3) : | 23.7 |
| RSI | RSI(14): 42.5 |
|||
| 52-week | High : | 2.26 | Low : | 0.4 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALXO ] has closed above bottom band by 23.3%. Bollinger Bands are 47% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.35 - 1.36 | 1.36 - 1.37 |
| Low: | 1.16 - 1.17 | 1.17 - 1.18 |
| Close: | 1.3 - 1.31 | 1.31 - 1.32 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Mon, 10 Nov 2025
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO) and Cencora (COR) - The Globe and Mail
Sat, 08 Nov 2025
Alx Oncology Earnings Call: Optimism Amid Challenges - TipRanks
Sat, 08 Nov 2025
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q3 2025 Earnings Call Transcript - Insider Monkey
Sat, 08 Nov 2025
ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... - Yahoo Finance
Fri, 07 Nov 2025
ALX Oncology Reports Promising Q3 2025 Results - TipRanks
Fri, 07 Nov 2025
Transcript : ALX Oncology Holdings Inc., Q3 2025 Earnings Call, Nov 07, 2025 - MarketScreener
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 73.4 (%) |
| Shares Short | 1,860 (K) |
| Shares Short P.Month | 1,580 (K) |
| EPS | -2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.8 % |
| Return on Equity (ttm) | -104.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -105 (M) |
| Levered Free Cash Flow | -71 (M) |
| PE Ratio | -0.61 |
| PEG Ratio | 0 |
| Price to Book value | 1.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|